Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
RAPT Therapeutics (RAPT) Stock Price & Analysis
266 Followers
RAPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.88 - $27.35
Previous Close$3.95
Volume583.55K
Average Volume (3M)949.21K
Market Cap
$137.87M
Enterprise Value-$39.45M
Total Cash (Recent Filing)$184.78M
Total Debt (Recent Filing)$7.46M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 08, 2024EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.07
Shares Outstanding34,903,476
10 Day Avg. Volume728,605
30 Day Avg. Volume949,211
Standard Deviation0.31
R-Squared0.00856
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.82
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-25.83
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$14.75Price Target Upside264.20% Upside
Rating ConsensusHold
Number of Analyst Covering7
RAPT Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Development And Regulatory MilestonesRAPT is preparing to reveal comprehensive safety and efficacy data from their Phase 2 studies in atopic dermatitis and asthma, which could provide significant insights into the treatments' potential.
Financial PerformanceRAPT's reported net loss was narrower than expected, indicating better cost management and potential for improved financial stability.
Partnership And Commercialization ProspectsRAPT's active search for strategic partnerships to advance their oncology program suggests confidence in their drug candidates and could lead to value-creating collaborations.
Bears Say
Clinical Trial SetbacksSerious adverse event in the AD trial has led to FDA's full clinical hold, creating significant uncertainty for the drug's future.
Financial RisksDwindling cash runway and the likelihood of additional dilutive funding necessary at a high discount could negatively impact shareholder value.
Operational ChallengesSlow enrollment in the AD trial and potential equity dilution from financing needs pose major challenges to the company's operational efficiency.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RAPT FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was $3.88 and its highest was $27.35 in the past 12 months.
What is RAPT Therapeutics’s market cap?
Currently, no data Available
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 69 days.
How were RAPT Therapeutics’s earnings last quarter?
RAPT Therapeutics released its earnings results on May 09, 2024. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$0.809 by $0.019.
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate is -$0.74.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 34,903,477 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
RAPT Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$0.809. Following the earnings report the stock price went down -41.604%.
Which hedge fund is a major shareholder of RAPT Therapeutics?
Among the largest hedge funds holding RAPT Therapeutics’s share is Perceptive Advisors LLC. It holds RAPT Therapeutics’s shares valued at 11M.
---
RAPT Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$14.75 (264.20% Upside)
$14.75 (264.20% Upside)
Blogger Sentiment
Bullish
RAPT Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 352.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.58%
12-Months-Change
Fundamentals
Return on Equity
-67.21%
Trailing 12-Months
Asset Growth
-37.25%
Trailing 12-Months
Company Description
RAPT Therapeutics
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
---
RAPT Stock 12 Month Forecast
Average Price Target
$14.75
▲(264.20% Upside)
Technical Analysis
Best Analysts Covering RAPT
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-36.86%
assigned a buy rating 3 months ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -36.86% per trade.
---